Literature DB >> 25917499

Optimal timing of first posttreatment FDG PET/CT in head and neck squamous cell carcinoma.

Alan S Leung1,2, Tanya J Rath1, Marion A Hughes1, Seungwon Kim3, Barton F Branstetter1,3.   

Abstract

BACKGROUND: The optimal timing for the initial posttreatment fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT scan after definitive treatment of head and neck squamous cell carcinoma (HNSCC) is unclear.
METHODS: We conducted a retrospective review of 247 patients with definitively treated nonmetastatic HNSCC. First posttreatment PET/CT scans were grouped into: <7 weeks, 7 to 10 weeks, 11 to 14 weeks, and ≥15 weeks. Scans were categorized as positive or negative and accuracy of scans was calculated for each group using biopsy, subsequent imaging, or clinical follow-up for 1 year after treatment as a reference standard.
RESULTS: Sixty-seven of the 247 patients (27.1%) had treatment failure. Scans performed at <7 weeks were less accurate than all other time intervals (p < .05). Scans performed at all other intervals were similar in accuracy.
CONCLUSION: First posttreatment PET/CT can be obtained as early as 2 months after therapy. Scans performed earlier than 2 months have lower accuracy.
© 2015 Wiley Periodicals, Inc. Head Neck 38: E853-E858, 2016. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  fluorodeoxyglucose (FDG); head and neck squamous cell carcinoma; positron emission tomography (PET)/CT; posttreatment; timing

Mesh:

Substances:

Year:  2015        PMID: 25917499     DOI: 10.1002/hed.24112

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  13 in total

1.  Qualitative interpretation of PET scans using a Likert scale to assess neck node response to radiotherapy in head and neck cancer.

Authors:  Johanna Sjövall; Ulrika Bitzén; Elisabeth Kjellén; Per Nilsson; Peter Wahlberg; Eva Brun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-02       Impact factor: 9.236

2.  Evaluation of neck node response after radiotherapy: minimizing equivocal results.

Authors:  Remco de Bree; Otto S Hoekstra
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04       Impact factor: 9.236

3.  Posttreatment Imaging in Patients with Head and Neck Cancer without Clinical Evidence of Recurrence: Should Surveillance Imaging Extend Beyond 6 Months?

Authors:  A Gore; K Baugnon; J Beitler; N F Saba; M R Patel; X Wu; B J Boyce; A H Aiken
Journal:  AJNR Am J Neuroradiol       Date:  2020-06-18       Impact factor: 3.825

4.  Second-look PET-CT following an initial incomplete PET-CT response to (chemo)radiotherapy for head and neck squamous cell carcinoma.

Authors:  Robin J D Prestwich; Moses Arunsingh; Jim Zhong; Karen E Dyker; Sriram Vaidyanathan; Andrew F Scarsbrook
Journal:  Eur Radiol       Date:  2019-08-29       Impact factor: 5.315

5.  Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma.

Authors:  D A Krieger; P A Hudgins; G K Nayak; K L Baugnon; A S Corey; M R Patel; J J Beitler; N F Saba; Y Liu; A H Aiken
Journal:  AJNR Am J Neuroradiol       Date:  2017-03-31       Impact factor: 3.825

6.  Discordance Between Oncology Clinician-Perceived and Radiologist-Intended Meaning of the Postradiotherapy Positron Emission Tomography/Computed Tomography Freeform Report for Head and Neck Cancer.

Authors:  Zachary Patel; Jennifer A Schroeder; Paul M Bunch; Joni K Evans; Cole R Steber; Adam G Johnson; Joshua C Farris; Ryan T Hughes
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2022-10-01       Impact factor: 8.961

7.  18F-FDG-PET/CT in the quantification of photon radiation therapy-induced vasculitis.

Authors:  Austin J Borja; Emily C Hancin; Alexandra D Dreyfuss; Vincent Zhang; Toby Mathew; Chaitanya Rojulpote; Thomas J Werner; Shivaraj Patil; Karthik Gonuguntla; Alexander Lin; Steven J Feigenberg; Samuel Swisher-McClure; Abass Alavi; Mona-Elisabeth Revheim
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-02-25

8.  18F-FDG-PET/CT for the detection of disease in patients with head and neck cancer treated with radiotherapy.

Authors:  Nils Helsen; Dessie Roothans; Bert Van Den Heuvel; Tim Van den Wyngaert; Danielle Van den Weyngaert; Laurens Carp; Sigrid Stroobants
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

Review 9.  Assessing Novel Drugs and Radiation Technology in the Chemoradiation of Oropharyngeal Cancer.

Authors:  Agostino Cristaudo; Mitchell Hickman; Charles Fong; Paul Sanghera; Andrew Hartley
Journal:  Medicines (Basel)       Date:  2018-06-27

10.  F-18 FDG PET-CT for response evaluation in head and neck malignancy: Experience from a tertiary level hospital in south India.

Authors:  Justin Benjamin; Julie Hephzibah; Nylla Shanthly; Regi Oommen; David Mathew; Simon Pavamani; Janakiraman Rajnikanth
Journal:  Cancer Rep (Hoboken)       Date:  2021-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.